Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RITA B CHUANG

Allopathic & Osteopathic Physicians Family Medicine

NPI
1497854962
CMS profile
339716
Location
HENDERSON, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,401.79

64 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,301.79 63
Gift $100.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RITA B CHUANG

NPI 1497854962 · CMS profile ID 339716

Allopathic & Osteopathic Physicians / Family Medicine

HENDERSON, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497854962?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RITA B CHUANG, NPI 1497854962, CMS profile ID 339716. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497854962?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RITA B CHUANG, NPI 1497854962, CMS profile ID 339716. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497854962?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RITA B CHUANG, NPI 1497854962, CMS profile ID 339716, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1497854962?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

64 matching records · $1,401.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 64 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 64.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $18.3912/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915360267 CMS
Merck Sharp & Dohme LLC $16.4111/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944566313 CMS
PFIZER INC. $28.3711/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949445339 CMS
Lilly USA, LLC $15.4711/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918257461 CMS
AstraZeneca Pharmaceuticals LP $15.2910/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915482123 CMS
ABBVIE INC. $30.2810/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890761375 CMS
INTRA-SANA LABORATORIES $100.0010/18/2022 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964116879 CMS
IMPEL PHARMACEUTICALS INC. $21.7210/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962327243 CMS
INTRA-SANA LABORATORIES $18.0510/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964115411 CMS
AstraZeneca Pharmaceuticals LP $17.0010/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914774461 CMS
AstraZeneca Pharmaceuticals LP $17.5610/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915159943 CMS
Amgen Inc. $12.7810/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939818707 CMS
Novo Nordisk Inc $22.9909/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898720837 CMS
AstraZeneca Pharmaceuticals LP $15.9209/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915177407 CMS
AstraZeneca Pharmaceuticals LP $13.1209/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915155407 CMS
Biohaven Pharmaceutical Holding Company Ltd. $23.0608/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923561729 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.8108/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887469593 CMS
Dexcom, Inc. $22.7308/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957314373 CMS
Lilly USA, LLC $12.9208/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918206635 CMS
AstraZeneca Pharmaceuticals LP $14.3608/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915446049 CMS
AstraZeneca Pharmaceuticals LP $17.7308/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915350003 CMS
AstraZeneca Pharmaceuticals LP $13.7707/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915003459 CMS
Inogen, Inc. $8.8607/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964102197 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.2507/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959495363 CMS
ABBVIE INC. $27.5007/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890761373 CMS
kaleo, Inc. $19.4306/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941035731 CMS
Esperion Therapeutics, Inc. $19.4506/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947248801 CMS
ABBVIE INC. $21.9206/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890761371 CMS
Biohaven Pharmaceutical Holding Company Ltd. $22.4605/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923561727 CMS
AstraZeneca Pharmaceuticals LP $18.9305/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914892735 CMS
kaleo, Inc. $15.2905/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941035735 CMS
Amgen Inc. $21.2605/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939163953 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.8905/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887469595 CMS
ABBVIE INC. $18.1605/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890761369 CMS
Dexcom, Inc. $19.4904/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957314381 CMS
Horizon Therapeutics plc $22.1104/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937604985 CMS
AstraZeneca Pharmaceuticals LP $16.5204/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915771021 CMS
AstraZeneca Pharmaceuticals LP $16.1404/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914635539 CMS
Biohaven Pharmaceutical Holding Company Ltd. $21.8004/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923561725 CMS
Novo Nordisk Inc $20.2604/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898621447 CMS
ABBVIE INC. $26.9704/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890761367 CMS
Bayer HealthCare Pharmaceuticals Inc. $24.4604/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930215245 CMS
GlaxoSmithKline, LLC. $12.6003/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944840169 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.1903/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959608185 CMS
Amgen Inc. $14.4503/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939818703 CMS
Novartis Pharmaceuticals Corporation $22.3303/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893572887 CMS
AstraZeneca Pharmaceuticals LP $12.6703/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915890247 CMS
ABBVIE INC. $26.7903/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890761365 CMS
Biohaven Pharmaceutical Holding Company Ltd. $26.1303/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923561723 CMS
AstraZeneca Pharmaceuticals LP $11.7002/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915780615 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,839.57 139
PY2020 $1,433.13 89
PY2021 $1,935.28 96
PY2022 $1,401.79 64
PY2023 $3,265.71 67
PY2024 $1,619.65 16
PY2025 $876.10 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $109,405.49 16
PY2021 Principal investigator $79,823.05 120
PY2020 Principal investigator $98,717.42 98
PY2019 Recipient $901.66 10
PY2019 Principal investigator $172,883.69 87

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

97 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $1,740.63 12/31/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670120635
Principal investigator 1 Novo Nordisk AS $7,474.68 12/23/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457049
Principal investigator 1 Eli Lilly and Company $10.42 12/11/2019 Non-covered Recipient Entity
SYNEXUS CENTRAL ARIZONA MEDICAL ASSOCIATES PC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 654294481
Principal investigator 1 Novo Nordisk AS $6,530.76 12/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457047
Principal investigator 1 Novo Nordisk AS $24.99 12/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706712825
Principal investigator 1 Eli Lilly and Company $1,098.73 11/21/2019 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 654289307
Principal investigator 1 Novo Nordisk AS $24.99 11/21/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713731
Principal investigator 1 Allergan Inc. $955.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670099393
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670099469
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100019
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670101069
Principal investigator 1 Allergan Inc. $1,767.00 11/19/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670102655
Principal investigator 1 Novo Nordisk AS $24.99 11/08/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $875.00 11/06/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,575.00 11/06/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738727
Principal investigator 1 Allergan Inc. $8,036.00 11/04/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670094143
Principal investigator 1 Allergan Inc. $5,685.00 11/01/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670094115
Principal investigator 1 Novo Nordisk AS $24.99 11/01/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713653
Principal investigator 1 Allergan Inc. $1,767.00 10/29/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670092189
Principal investigator 1 Novo Nordisk AS $8,523.36 10/29/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457037
Principal investigator 1 Novo Nordisk AS $24.99 10/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713583
Principal investigator 1 Novo Nordisk AS $288.00 10/15/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457035
Principal investigator 1 Novo Nordisk AS $24.99 10/07/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713581
Principal investigator 1 Novo Nordisk AS $12,282.30 09/26/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,324.00 09/11/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738725
Principal investigator 1 Novo Nordisk AS $8,858.16 08/30/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,808.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,902.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738723
Principal investigator 1 Novo Nordisk AS $49.98 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713449
Principal investigator 1 Novo Nordisk AS $12.75 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713455
Principal investigator 1 Novo Nordisk AS $26.00 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713457
Principal investigator 1 Novo Nordisk AS $74.95 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713459
Principal investigator 1 Novo Nordisk AS $39.50 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713461
Principal investigator 1 Novo Nordisk AS $18.30 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713463
Principal investigator 1 Novo Nordisk AS $180.00 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713465
Principal investigator 1 Novo Nordisk AS $54.95 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713467
Principal investigator 1 Novo Nordisk AS $64.90 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713469
Principal investigator 1 Novo Nordisk AS $28.45 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713471
Principal investigator 1 Novo Nordisk AS $32.50 08/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713473
Principal investigator 1 Novo Nordisk AS $1,000.00 07/30/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
NN1250-4252 No dispute reported 06/30/2026 692457013
Principal investigator 1 Novo Nordisk AS $1,000.00 07/30/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
NN1250-4252 No dispute reported 06/30/2026 692457015
Principal investigator 1 Novo Nordisk AS $7,301.88 07/30/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457039
Principal investigator 1 Novo Nordisk AS $288.00 07/30/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457041
Principal investigator 1 Novo Nordisk AS $12,260.42 07/25/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
NN1250-4252 No dispute reported 06/30/2026 692457011
Principal investigator 1 Novo Nordisk AS $24.99 07/16/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,903.00 07/11/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738719
Principal investigator 1 Eli Lilly and Company $1,000.00 07/03/2019 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654289649
Principal investigator 1 Novo Nordisk AS $49.98 06/28/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713405
Principal investigator 1 Novo Nordisk AS $24.99 06/26/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713375
Principal investigator 1 Novo Nordisk AS $187.50 06/25/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457031
Principal investigator 1 Novo Nordisk AS $5,991.84 06/25/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457033
Principal investigator 1 Novo Nordisk AS $24.99 06/24/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713373
Principal investigator 1 Novo Nordisk AS $24.99 06/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713367
Recipient AbbVie, Inc. $18.93 06/03/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647628033
Recipient AbbVie, Inc. $28.48 06/03/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647628035
Recipient AbbVie, Inc. $18.96 06/03/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647628037
Recipient AbbVie, Inc. $22.95 06/03/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647628039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,400.00 06/03/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738717
Principal investigator 1 Novo Nordisk AS $7,864.02 05/28/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457029
Principal investigator 1 Novo Nordisk AS $26.00 05/20/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,088.00 05/01/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738715
Principal investigator 1 Novo Nordisk AS $24.99 04/29/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706713071
Principal investigator 1 Novo Nordisk AS $1,409.40 04/25/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
NN1250-4252 No dispute reported 06/30/2026 692457009
Principal investigator 1 Novo Nordisk AS $5,015.52 04/25/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457025
Principal investigator 1 Novo Nordisk AS $350.00 04/25/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457027
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,223.04 04/12/2019 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE INC
safety and efficacy linagliptin vs SU No dispute reported 06/30/2026 704146173
Recipient AbbVie, Inc. $36.06 04/05/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647628021
Recipient AbbVie, Inc. $18.75 04/05/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647628023
Recipient AbbVie, Inc. $476.04 04/05/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647628025
Recipient AbbVie, Inc. $58.57 04/05/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647628029
Recipient AbbVie, Inc. $18.86 04/05/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647628031
Recipient AbbVie, Inc. $204.06 04/04/2019 Covered Recipient Physician M16-100 No dispute reported 06/30/2026 647628027
Principal investigator 1 Novo Nordisk AS $24.99 04/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706712999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,146.00 04/03/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.00 04/03/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,552.00 03/28/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,214.00 03/28/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $952.00 03/28/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.00 03/28/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,214.00 03/28/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.00 03/28/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,224.00 03/28/2019 Non-covered Recipient Entity
SYNEXUS US
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639738709
Principal investigator 1 Novo Nordisk AS $625.50 03/26/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
NN1250-4252 No dispute reported 06/30/2026 692457007
Principal investigator 1 Novo Nordisk AS $3,639.60 03/26/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457021
Principal investigator 1 Novo Nordisk AS $288.00 03/26/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457023
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,250.00 03/22/2019 Non-covered Recipient Entity
Synexus Clinical Research US Inc
safety and efficacy linagliptin vs SU No dispute reported 06/30/2026 704143281
Principal investigator 1 Novo Nordisk AS $24.99 03/19/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706712951
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 03/15/2019 Non-covered Recipient Entity
Clinical Research Advantage, Inc.
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 685007315
Principal investigator 1 Novo Nordisk AS $26.00 03/06/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706712915
Principal investigator 1 Novo Nordisk AS $39.50 03/06/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706712917
Principal investigator 1 Novo Nordisk AS $18.30 03/06/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706712919
Principal investigator 1 Novo Nordisk AS $64.90 03/06/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706712921
Principal investigator 1 Novo Nordisk AS $1,771.74 02/26/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457019
Principal investigator 1 Novo Nordisk AS $1,251.00 02/21/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
NN1250-4252 No dispute reported 06/30/2026 692457005
Principal investigator 1 Novo Nordisk AS $1.70 02/11/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 706712863
Principal investigator 1 Novo Nordisk AS $6,301.80 01/24/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
NN1250-4252 No dispute reported 06/30/2026 692457003
Principal investigator 1 Novo Nordisk AS $5,647.86 01/24/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
EX9536-4388 No dispute reported 06/30/2026 692457017